- Home
- KIM vs WST Comparison
KIM vs WST Comparison
Compare KIM & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- WST
- Stock Information
- Founded
- KIM 1958
- WST 1923
- Country
- KIM United States
- WST United States
- Employees
- KIM N/A
- WST N/A
- Industry
- KIM Real Estate Investment Trusts
- WST Medical/Dental Instruments
- Sector
- KIM Real Estate
- WST Health Care
- Exchange
- KIM Nasdaq
- WST Nasdaq
- Market Cap
- KIM 14.1B
- WST 20.1B
- IPO Year
- KIM 1991
- WST N/A
- Fundamental
- Price
- KIM $20.25
- WST $260.84
- Analyst Decision
- KIM Buy
- WST Strong Buy
- Analyst Count
- KIM 10
- WST 9
- Target Price
- KIM $24.20
- WST $354.50
- AVG Volume (30 Days)
- KIM 5.0M
- WST 775.7K
- Earning Date
- KIM 10-30-2025
- WST 10-23-2025
- Dividend Yield
- KIM 5.14%
- WST 0.34%
- EPS Growth
- KIM 57.13
- WST 0.17
- EPS
- KIM 0.83
- WST 6.75
- Revenue
- KIM $2,123,057,000.00
- WST $3,017,900,000.00
- Revenue This Year
- KIM $4.86
- WST $6.97
- Revenue Next Year
- KIM $3.18
- WST $6.11
- P/E Ratio
- KIM $24.32
- WST $38.53
- Revenue Growth
- KIM 8.14
- WST 4.92
- 52 Week Low
- KIM $17.93
- WST $187.43
- 52 Week High
- KIM $25.83
- WST $348.90
- Technical
- Relative Strength Index (RSI)
- KIM 37.06
- WST 39.95
- Support Level
- KIM $20.16
- WST $258.93
- Resistance Level
- KIM $20.80
- WST $266.26
- Average True Range (ATR)
- KIM 0.40
- WST 9.07
- MACD
- KIM -0.04
- WST -3.18
- Stochastic Oscillator
- KIM 12.60
- WST 10.59
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.